Abstract 392TiP
Background
Hypopharyngeal cancer is relatively rare, accounting for only 3% of head and neck cancers. A majority of the patients (pts) present at an advanced stage with a 5-year overall survival of 40%. Despite improvement in local regional control with neoadjuvant therapy, distant metastasis led to poor outcomes in hypopharyngeal cancer. Individualized adjuvant therapy based on pathologic complete response (pCR) and CD8+ T cell infiltration may be a promising strategy for pts after neoadjuvant therapy. Thus, we conducted a phase II study (ChiCTR2200055939) to evaluate the efficacy and safety of neoadjuvant and individualized adjuvant therapy and explore the correlation between tertiary lymphoid structures (TLS) and efficacy/immune microenvironment in pts with locally advanced hypopharyngeal cancer.
Trial design
In the prospective, open-label, single-arm phase II study, pts who have histologically or cytologically confirmed stage II-IVa hypopharyngeal cancer without recurrent/metastatic disease, ECOG performance status of 0-1, and predicted survival >3 months are eligible. Pts will intravenously receive 2-cycle neoadjuvant therapy with pembrolizumab (200 mg), albumin-bound paclitaxel (260 mg/m2), and cisplatin (100 mg/m2) on day 1 every 3 weeks. Surgical resection will be scheduled within 21-28 days after the final dose of neoadjuvant therapy. If postoperative pathology shows a pCR, pembrolizumab will be given as adjuvant therapy for 15 cycles. Pts with non-pCR but CD8+ cell density increased ≥20% from baseline will receive adjuvant radiotherapy (50-60Gy) plus pembrolizumab for 15 cycles; otherwise, non-pCR pts will withdraw from the study and receive conventional concurrent chemoradiotherapy. The primary endpoint is 12-month recurrence-free survival (RFS). Secondary endpoints are 18- and 24-month RFS, median RFS, pCR rate, and safety. Exploratory endpoints include the correlation between TLS and pathological response/RFS/immune microenvironment (eg, CD8+ cells, B/T lymphocytes). The phase 2 trial is ongoing.
Clinical trial identification
ChiCTR220005593p.
Legal entity responsible for the study
The Sixth Medical Center of Chinese PLA General Hospital.
Funding
Wu Jieping Medical Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract